• 1
    Wellings SR, Jensen HM, Marcum RG. Atlas of subgross pathology of the human breast with special reference to possible cancerous lesions. J. Natl Cancer Inst. 1975; 55; 231273.
  • 2
    Hanby AM. Aspects of molecular phenotype and its correlations with breast cancer behaviour and taxonomy. Br. J. Cancer 2005; 92; 613617.
  • 3
    Pritt B, Ashikaga T, Oppenheimer RG, Weaver DL. Influence of breast cancer histology on the relationship between ultrasound and pathology tumor size measurements. Mod. Pathol. 2004; 17; 905910.
  • 4
    Wheeler DT, Tai LH, Bratthauer GL, Waldner DL, Tavassoli FA. Tubulolobular carcinoma of the breast: an analysis of 27 cases of a tumor with a hybrid morphology and immunoprofile. Am. J. Surg. Pathol. 2004; 28; 15871593.
  • 5
    Bratthauer GL, Moinfar F, Stamatakos MD et al. Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias. Hum. Pathol. 2002; 33; 620627.
  • 6
    Wenzel C, Bartsch R, Hussian D et al. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. Breast Cancer Res. Treat. 2007; 104; 109114.
  • 7
    Turashvili G, Bouchal J, Baumforth K et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007; 7; 55.
  • 8
    Savanis G, Simatos G, Tzaida O et al. Gastrointestinal tract metastasis as first presentation of breast cancer. J BUON 2006; 11; 7981.
  • 9
    Kadivar M, Joulaee A, Kashkouli MB, Kharazi HH, Kalantari M, Kumar PV. Orbital metastasis as the first presentation of nonpalpable invasive lobular carcinoma of the breast. Breast J. 2006; 12; 7576.
  • 10
    Giagounidis AA, Heinsch M, Von Barany RU, Erlemannb R, Aul C. Breast cancer metastasis to the aortic vessel wall. Onkologie 2005; 28; 369.
  • 11
    El Khoury M, Cherel P, Becette V et al. Unusual soft-tissue metastasis of an invasive lobular carcinoma mimicking fasciitis. Am. J. Roentgenol. 2004; 182; 745747.
  • 12
    Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 2000; 88; 25612569.
  • 13
    Li CI, Daling JR, Malone KE et al. Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. Cancer Epidemiol. Biomarkers Prev. 2006; 15; 946954.
  • 14
    Lakhani SR, Audretsch W, Cleton-Jensen AM et al. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)? Eur. J. Cancer 2006; 42; 22052211.
  • 15
    Li CI, Malone KE, Saltzman BS, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. Cancer 2006; 106; 21042112.
  • 16
    Urban JA. Bilaterality of cancer of the breast. Biopsy of the opposite breast. Cancer 1967; 20; 18671870.
  • 17
    Rosen PP, Senie R, Schottenfeld D, Ashikari R. Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment. Ann. Surg. 1979; 189; 377382.
  • 18
    Rosen PP, Kosloff C, Lieberman PH, Adair F, Braun DW Jr. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am. J. Surg. Pathol. 1978; 2; 225251.
  • 19
    Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 2003; 361; 125129.
  • 20
    Marshall LM, Hunter DJ, Connolly JL et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol. Biomarkers Prev. 1997; 6; 297301.
  • 21
    Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004; 6; R149R156.
  • 22
    Krecke KN, Gisvold JJ. Invasive lobular carcinoma of the breast: mammographic findings and extent of disease at diagnosis in 184 patients. Am. J. Roentgenol. 1993; 161; 957960.
  • 23
    Ma L, Fishell E, Wright B, Hanna W, Allan S, Boyd NF. Case–control study of factors associated with failure to detect breast cancer by mammography. J. Natl Cancer Inst. 1992; 84; 781785.
  • 24
    Kepple J, Layeeque R, Klimberg VS et al. Correlation of magnetic resonance imaging and pathologic size of infiltrating lobular carcinoma of the breast. Am. J. Surg. 2005; 190; 623627.
  • 25
    Cornford EJ, Wilson AR, Athanassiou E et al. Mammographic features of invasive lobular and invasive ductal carcinoma of the breast: a comparative analysis. Br. J. Radiol. 1995; 68; 450453.
  • 26
    Helvie MA, Paramagul C, Oberman HA, Adler DD. Invasive lobular carcinoma. Imaging features and clinical detection. Invest. Radiol. 1993; 28; 202207.
  • 27
    Weinstein SP, Orel SG, Heller R et al. MR imaging of the breast in patients with invasive lobular carcinoma. Am. J. Roentgenol. 2001; 176; 399406.
  • 28
    Boetes C, Veltman J, Van Die L, Bult P, Wobbes T, Barentsz JO. The role of MRI in invasive lobular carcinoma. Breast Cancer Res. Treat. 2004; 86; 3137.
  • 29
    Munot K, Dall B, Achuthan R, Parkin G, Lane S, Horgan K. Role of magnetic resonance imaging in the diagnosis and single-stage surgical resection of invasive lobular carcinoma of the breast. Br. J. Surg. 2002; 89; 12961301.
  • 30
    Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978; 42; 737769.
  • 31
    Leibl S, Regitnig P, Moinfar F. Flat epithelial atypia (DIN 1a, atypical columnar change): an underdiagnosed entity very frequently coexisting with lobular neoplasia. Histopathology 2007; 50; 859865.
  • 32
    Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am. J. Surg. Pathol. 2007; 31; 417426.
  • 33
    Foote FW, Stewart FW. Lobular carcinoma in situ. Am. J. Pathol. 1941; 491495.
  • 34
    Mohsin SK, O’Connell P, Allred DC, Libby AL. Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Breast Cancer Res. Treat. 2005; 90; 249256.
  • 35
    Rudas M, Neumayer R, Gnant MF, Mittelbock M, Jakesz R, Reiner A. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur. J. Cancer 1997; 33; 3944.
  • 36
    Somerville JE, Clarke LA, Biggart JD. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J. Clin. Pathol. 1992; 45; 1620.
  • 37
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403410.
  • 38
    NHSBSP Publication Number 58. Pathology reporting of breast disease. Sheffield: NHS Cancer Screening Programmes and The Royal College of Pathologists, 2005.
  • 39
    Singletary SE, Patel-Parekh L, Bland KI. Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base. Ann. Surg. 2005; 242; 281289.
  • 40
    Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer: II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 1992; 20; 479489.
  • 41
    Martinez V, Azzopardi JG. Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 1979; 3; 467488.
  • 42
    Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 1975; 36; 185.
  • 43
    Roylance R, Gorman P, Harris W et al. Comparative hybridisation of breast tumours stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res. 1999; 59; 14331436.
  • 44
    Nishizaki T, Chew K, Chu L et al. Genomic alterations in lobular breast cancer by comparative genomic hybridization. Int. J. Cancer 1997; 74; 513517.
  • 45
    Radhi JM. Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR. Histopathology 2000; 36; 156160.
  • 46
    Middleton LP, Palacios DM, Bryant BR, Krebs P, Otis CN, Merino MJ. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am. J. Surg. Pathol. 2000; 24; 16501656.
  • 47
    Walford N, Ten Velden J. Histiocytoid breast carcinoma: an apocrine variant of lobular carcinoma. Histopathology 1989; 14; 515522.
  • 48
    Fisher ER, Gregorio RM, Redmond C, Fisher B. Tubulolobular invasive breast cancer: a variant of lobular invasive cancer. Hum. Pathol. 1977; 8; 679683.
  • 49
    Marchio C, Sapino A, Arisio R, Bussolati G. A new vision of tubular and tubulo-lobular carcinomas of the breast, as revealed by 3-D modelling. Histopathology 2006; 48; 556562.
  • 50
    Du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, Blamey RW. Invasive lobular carcinomas of the breast – the prognosis of histopathological subtypes. Br. J. Cancer 1989; 60; 605609.
  • 51
    Pereira H, Pinder SE, Sibbering DM et al. Pathological prognostic factors in breast cancer: IV. Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995; 27; 219226.
  • 52
    Kuroda H, Tamaru J, Takeuchi I et al. Expression of E-cadherin, alpha-catenin, and beta-catenin in tubulolobular carcinoma of the breast. Virchows Arch. 2006; 448; 500505.
  • 53
    Buerger H, Simon R, Schafer KL et al. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast. Mol. Pathol. 2000; 53; 118121.
  • 54
    Berx G, Cleton-Jansen AM, Strumane K et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996; 13; 19191925.
  • 55
    Leeuw WJFd, Berx G, Vos CBJ et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J. Pathol. 1997; 183; 404411.
  • 56
    Moll R, Mitze M, Frixen U, Birchmeier W. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am. J. Pathol. 1993; 142; 987993.
  • 57
    Vos CBJ, Cleton-Jansen AM, Berx G et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br. J. Cancer 1997; 76; 11311133.
  • 58
    Berx G, Nollet F, Roy FV. Dysregulation of the E-cadherin/catenin complex by irreversible mutations in human carcinomas. Cell Adhes. Commun. 1998; 6; 171184.
  • 59
    Berx G, Cleton-Jansen AM, Nollet F et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 1995; 14; 61076115.
  • 60
    Huiping C, Sigurgeirsdottir J, Jonasson J et al. Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. Br. J. Cancer 1999; 81; 11031110.
  • 61
    Droufakou S, Deshmane V, Hanby A, Tomlinson I, Hart I. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int. J. Cancer 2001; 92; 404408.
  • 62
    Rasbridge SA, Gillett CE, Sampson SA, Walsh FS, Millis RR. Epithelial (E-) and Placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. J. Pathol. 1993; 169; 245250.
  • 63
    Boller K, Vestweber D, Kemler R. Cell adhesion molecule uvomorulin is localised in the intermediate junctions of the adult intestinal epithelial cells. J. Cell Biol. 1985; 100; 327332.
  • 64
    Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251; 14511455.
  • 65
    Gumbiner B, Stevenson B, Grimaldi A. The role of the cell adhesion molecule uvomorulin in the formation and maintenance of the epithelial junctional complex. J. Cell Biol. 1988; 107; 15751587.
  • 66
    Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int. J. Cancer 2001; 92; 404408.
  • 67
    Salomon D, Sacco PA, Roy SG et al. Regulation of β-catenin levels and the localisation by overexpression of plakoglobin and inhibition of the Ubiquitin–Proteosome system. J. Cell Biol. 1997; 139; 13251335.
  • 68
    Simcha I, Shtutman M, Salomon D et al. Differential nuclear translocation and transactivation potential of β-catenin and plakoglobin. J. Cell Biol. 1998; 141; 14331448.
  • 69
    Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B. Activation of β-catenin-Tcf signalling in colon cancer by mutations in β-catenin or APC. Science 1997; 275; 17871790.
  • 70
    Shtutman M, Zhurinsky J, Simcha I et al. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc. Natl Acad. Sci. U.S.A. 1999; 96; 55225527.
  • 71
    Gillett CE, Miles DW, Ryder K et al. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J. Pathol. 2001; 193; 433441.
  • 72
    Tan DSP, Potts HWW, Leong ACK et al. The biological and prognostic significance of cell polarity and E-cadherin in grade I infiltrating ductal carcinoma of the breast. J. Pathol. 1999; 189; 2027.
  • 73
    Vos C, Haar Nt, Rosenberg C et al. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br. J. Cancer 1999; 81; 14101418.
  • 74
    Roylance R, Gorman P, Papior T et al. A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH. Oncogene 2006; 25; 65446553.
  • 75
    Reis-Filho JS, Simpson PT, Jones C et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J. Pathol. 2005; 207; 113.
  • 76
    Reis-Filho JS, Simpson PT, Turner NC et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin. Cancer Res. 2006; 12; 66526662.
  • 77
    Elbauomy Elsheikh S, Green AR, Lambros MB et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007; 9; R23.
  • 78
    Keller G, Vogelsang H, Becker I et al. Diffuse gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am. J. Pathol. 1999; 155; 337342.